- People
- Offices
- Capabilities
back- Capabilities
- Corporate, Finance and Investments
- back
- Corporate, Finance and Investments
- Overview
- Activist Defense
- Capital Markets
- Construction and Procurement
- Corporate Governance
- Emerging Companies and Venture Capital
- Employee Benefits and Executive Compensation
- Energy and Infrastructure Projects
- Financial Restructuring
- Fund Finance
- Global Human Capital and Compliance
- Investment Funds and Asset Management
- Leveraged Finance
- Mergers and Acquisitions (M&A)
- Middle East and Islamic Finance and Investment
- Private Equity
- Public Companies
- Real Estate
- Structured Finance and Securitization
- Tax
- Technology Transactions
- Government Matters
- back
- Government Matters
- Overview
- Antitrust
- Data, Privacy and Security
- Environmental, Health and Safety
- FDA and Life Sciences
- Government Advocacy and Public Policy
- Government Contracts
- Healthcare
- Innovation Protection
- International Trade
- National Security and Corporate Espionage
- Securities Enforcement and Regulation
- Special Matters and Government Investigations
- Trial and Global Disputes
- back
- Trial and Global Disputes
- Overview
- Antitrust
- Appellate, Constitutional and Administrative Law
- Bankruptcy and Insolvency Litigation
- Class Action Defense
- Commercial Litigation
- Corporate and Securities Litigation
- E-Discovery
- Global Construction and Infrastructure Disputes
- Innovation Protection
- Intellectual Property
- International Arbitration and Litigation
- Labor and Employment
- Product Liability
- Professional Liability
- Toxic & Environmental Torts
- Industries / Issues
- back
- Industries / Issues
- Automotive, Transportation and Mobility
- Energy Transition
- Energy
- Financial Services
- Food and Beverage
- Higher Education
- Life Sciences and Healthcare
- Technology
- Artificial Intelligence (AI) and Machine Learning
- Buy American
- Crisis Management
- Doing Business in Latin America
- Environmental Agenda
- Environmental, Social and Governance (ESG)
- Focus on Women's Health
- Russia/Ukraine
- Special Purpose Acquisition Companies (SPACs)
- Careers
- News & Insights
- About
- Languages
Insights 283 results
Client Alert
June 3, 2026
FDA Issues New Draft Guidance Addressing Communications with Payors
Client Alert
April 27, 2026
UK–U.S. Trade Under the Spotlight: Parliamentary Inquiry and New Anti-Coercion Powers Signal a Shift in UK Trade Strategy
Client Alert
April 20, 2026
FDA Reminds Sponsors and Researchers to Disclose Clinical Trial Results to ClinicalTrials.gov
Client Alert
Client Alert
March 9, 2026
EUROPE – Revision of the EU General Pharmaceutical Legislation – Regulatory Protections
Client Alert
February 9, 2026
FTC’s “Landmark” Settlement with Pharmacy Benefit Manager Express Scripts: Impact on Pharma
Article
January 28, 2026
IAPP Global Legislative Predictions 2026
Client Alert
January 21, 2026
2025 Year in Review: FDA Drug and Device Advertising and Promotion Enforcement
Article · Source: Daily Report
December 30, 2025
The One Big Beautiful Bill Act Explained: A Detailed Review of Key Changes for the Health Care Industry
Client Alert
December 29, 2025
Medicare and Medicaid Demos Seek to Impose MFN Pricing: An Overview of GENEROUS, GLOBE, and GUARD
Client Alert
December 19, 2025
President Trump Signs Executive Order to Reschedule Marijuana, Easing Research and Business Restrictions
Article · Source: Legal 500 Country Comparative Guides 2025
December 9, 2025
United States: Pharmaceutical Advertising